论文部分内容阅读
小细胞肺癌(SCLC)系一种低分化的恶性肿癌,约占全部肺癌的20—25％。晚近的实验发现此类型癌细胞具有急性白血病样生物学特性,对放、化疗非常敏感。当前虽尚未发现其特异性治疗方法,但通过以外科手术、放疗、药物等多学科综合疗法,可使初诊病人的客观缓解率达94％,中位生存期(MST)59周,2年无瘤生存率21％~1。说明SCLC患者长期生存的可能性大有希望。 一、手术疗法 由于SCLC较早的广泛转移,故大约2/3的初诊病人失去手术机会。近年来检测技术和综合疗法水平的提高,为SCLC手术开
Small cell lung cancer (SCLC) is a poorly differentiated malignant tumor that accounts for approximately 20-25% of all lung cancers. Recent experiments have found that this type of cancer cell has acute leukemia-like biological characteristics and is very sensitive to radiotherapy and chemotherapy. Although no specific treatment method has yet been discovered, the objective response rate of newly diagnosed patients can reach 94%, and the median survival period (MST) can be 59 weeks and 2 years without using multidisciplinary and comprehensive therapies such as surgery, radiotherapy, and drugs. The tumor survival rate was 21%~1. This shows that the possibility of long-term survival of SCLC patients is promising. First, Surgical Therapy Because of the early widespread metastasis of SCLC, about two-thirds of newly diagnosed patients have lost surgery. In recent years, the improvement of detection technology and comprehensive therapy for SCLC surgery